Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC
@braunmdphd.bsky.social @yalecancer.bsky.social #ChromophobeRCC #kcsm
www.onclive.com/view/defects...

Please join me in supporting the Chromophobe & Oncocytic Tumor Alliance’s Giving Tuesday campaign, raising funds for a #chromophobeRCC Scholar in Training Award with @theaacr.bsky.social. #kidneycancer #rarecancers givebutter.com/Yjzy10